TREMFYA (guselkumab) Delivers Sustained Clinical and Endoscopic Remission in Ulcerative Colitis Through Two Years
May 06, 2025
May 06, 2025
RARITAN, New Jersey, May 6 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
TREMFYA (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remi . . .
* * *
TREMFYA (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remi . . .